Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 90 In stock
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 M1LMb2NmdGxiVnnhZoltcXS7IFHzd4F6 NVPEUGpOOC1yLkWg{txO NHz1RmszPCCq M1\uSIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MmrGNlU3PjN5Nkm=
HepG2-HBV1.1 MmrQRZBweHSxc3nzJGF{e2G7 NVzhOYY{OC1yLkWg{txO MlrYNlQhcA>? M17u[olv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= M162[lI2PjZ|N{[5
HepG2.2.15 MVvGeY5kfGmxbjDBd5NigQ>? MnvRNE4yKM7:TR?= M2DyV|I1KGh? NUXYZndseHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v NVLKfml{OjV4NkO3Olk>
HepG2-HBV1.1 NF\6TXZHfW6ldHnvckBCe3OjeR?= NGryc24xNjFizszN NHrHXZQzPCCq MXfwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= M4W0UFI2PjZ|N{[5
HepG2-HBV1.1 NGf2UmZHfW6ldHnvckBCe3OjeR?= NEjMXFQxNjFizszN NFTvOlQ1QCCq NEjtdG5xem:vb4Tld{Bk\WyuIHX4Z5JmfGmxbjDv[kBp\XCjdHn0bZMhSiC4aYL1d{BvfWOuZX;jZZB{cWS|IHnud5Rm[WRib3[gbIVx[XSrdHnzJGIhfmm{dYOgSIFv\SCyYYL0bYNt\XN? NW[2VJhUOjV4NkO3Olk>
HepG2-HBV1.1 M2PqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHFXYMxNjFizszN MVexMVUh\A>? NIjhW2pqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckB1cW2nIHTldIVv\GWwdHz5 MYSyOVY3Ozd4OR?=
HepG2-HBV1.1 M4XJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrxdWExNjFizszN MmTQNU02KGR? Mme5bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= NEHmbHozPTZ4M{e2PS=>
HepG2-HBV1.1 NYPZTIU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljINE4yKM7:TR?= NIP3fZUyOi15MjDo NEDpU5FqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> MViyOVY3Ozd4OR?=
HepG2-HBV1.1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOwMlEh|ryP MVqxNk04OiCq M3fEdYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=> Mmn1NlU3PjN5Nkm=
Raji NXnEbZZRTnWwY4Tpc44hSXO|YYm= M162W|AvPcLizszN Ml2yO|IhcA>? MoTWZYJwdGm|aHXzJIF2fG:yaHHnfeKh NFPDcHQzPTR2NkO3Oy=>
SK-MEL-28  M2rXW2Z2dmO2aX;uJGF{e2G7 M3XHV|MxKG6P MmnaOkBp M{XkT4lv\HWlZYOgS|LjiJOPIHPlcIwu[3mlbHWgZZJz\XO2 M1XzblI2OzF|MEGw
H157 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrSTm1KSzVyPUGuNFMhyrFiMD6wOEBucXV{TR?= M2fMc|I2OjV5OUGx
Jurkat NF64W5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGxMVMhdk1? M{HiNVQ5yqCq MY\EUXNQ Mofa[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> NHnUNIMzPTF3NkG0Oi=>
CEM NUHaOIZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnmcWMyNTNibl2= NVrI[49WPDkEoHi= MXjEUXNQ MnPo[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> NEXZVoozPTF3NkG0Oi=>
P12 M4\oTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3pNU0{KG6P MUe0POKhcA>? M1XTSmROW09? MYHk[YNz\WG|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5 MUSyOVE2PjF2Nh?=
KB MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX5cm9[UUN3ME2wMlAxPDliwsGgNE4xODBzIN88US=> M3POUlI2ODV6NUK2
KBv200 (ABCB1) NIP2O3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HVTGlEPTB;MD6zOFYzKMLzIECuNFA3PiEQvF2= NV7SN|V{OjVyNUi1NlY>
SUDHL6  MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGx5qCK|ryP M{nMfFQ5Nzd{IHi= M3\CfIlvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MlXINlQ6PjF4MES=
SUDHL6  MXXGeY5kfGmxbjDBd5NigQ>? NUTGOVdFOeLCid88US=> Mom0O|IhcA>? NF3DPFJqdmS3Y3XzJJNq\26rZnnjZY51KGGyb4D0c5Rq[yCvb4LwbI9td2e7IHPoZY5o\XNiY3;0doV{fGWmIIfpeIghSkOOMUHBJJNqWk6D NFPr[XYzPDl4MU[wOC=>
HCT-116 MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPHTVUxRTVibl2= MnnZNlQ6Ojd6NUe=
SKNBe2C NFnxb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\iVZFKSzVyPUOyMljDuTRwMDDuUS=> NIfnNm4zPDl{MUmyNC=>
IGNR91 M33MfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj5TWM2OD1{ND6zxtEyNjdibl2= NFfsWYozPDl{MUmyNC=>
SKNAS M2PKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwNdMxNE4zKG6P M4DpXVI1QTJzOUKw
LAN1 MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXUeGFKSzVyPUKuN:KyOC5{IH7N NV3v[JhCOjR7MkG5NlA>
SHSY5Y NWi2OYVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XLVGlEPTB;OD6yxtExNjZibl2= M3;vXVI1QTJzOUKw
A549-WT NUfqNIVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fPb2lEPTB;MUmuOFM4KMLzIECuOVk1KCCwTR?= Ml[3NlQ5PTh6Mke=
A549-R NE\ofVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;BTWM2OD1zMj6xO|ghyrFiMD6zN|MhKG6P NHn3WWQzPDh3OEiyOy=>
MCF-7-WT NX2xSYU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj3TWM2OD1zNz63OVIhyrFiMD6yNVghKG6P NYfONGRjOjR6NUi4Nlc>
MCF-7-R MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nwTWlEPTB;NT61N|khyrFiMD6xOFQhKG6P NXm5XYlUOjR6NUi4Nlc>
A549-R M33k[mN6fG:2b4jpZ4l1gSCDc4PhfS=> NXTlXIZrUUN3ME2xNk4yPzhiwsGgNE4{OzNibl2= MYmyOFg2QDh{Nx?=
MCF-7-R M1TYfWN6fG:2b4jpZ4l1gSCDc4PhfS=> M2PVVWlEPTB;NT61N|khyrFiMD6xOFQhdk1? NXL4TYg1OjR6NUi4Nlc>
SW620 NFHqNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTdwOECgxtEhOC5yODDuUS=> NInFPYIzPDd{NkezPS=>
SW620/AD300 M1\hdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH4TWM2OD17MEmuOlAhyrFiOD65NUBvVQ>? Mmr4NlQ4OjZ5M{m=
HEK293/pcDNA3.1 NHPydIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLkSnlXUUN3ME2xMlQ2KMLzIECuNlAhdk1? M13HNVI1PzJ4N{O5
HEK293/ABCC1 M1vuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELlZ5VKSzVyPUG5MlI6KMLzIEKuNFghdk1? MkDpNlQ4OjZ5M{m=
TCC MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrMU28zPCCq NEnXR2RKSzVyPUewJI5O MYiyOFcyPjl2NB?=
TCC NX;0XYhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u1RlQ5KGh? M1vscWlEPTB;NUCgcm0> MYeyOFcyPjl2NB?=
HepG2/ADM MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzwTWM2OD1{Lke4OlPDuTBwMkO3NUDPxE1? MWSyOFcxPDV3Nh?=
HepG2 NFTjTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfrTFlKSzVyPUCuNFEyPcLzMD6wNFE4KM7:TR?= MVSyOFcxPDV3Nh?=
MCF-7/ADR MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXkOHVKSzVyPUSuOFgzPsLzMD6yNFcxKM7:TR?= MoLmNlQ4ODR3NU[=
MCF-7 NXW2UYYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M32xW2lEPTB;MD6wNVU6yrFyLkCwOlIh|ryP NHnveo8zPDdyNEW1Oi=>
A-172  NGTNOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;PNE4yyqEQvF2= M1rDWFI1Nzd{IHi= MnnkbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> NXXuR3YxOjR3M{CyN|U>
U-251MG MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDxNE4yyqEQvF2= NEW2SHQzPC95MjDo NVryT2Z1cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? MoTNNlQ2OzB{M{W=
DLD-1 M2fPT2Z2dmO2aX;uJGF{e2G7 NXrVephwOTByIH7N MVq0PEBp M1vBd5Bzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? NYHEV2c{OjR2MEO0OVM>
CCD18Co MY\GeY5kfGmxbjDBd5NigQ>? MX[xNFAhdk1? Ml3DOFghcA>? NYfJdVNOeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi M1S2cVI1PDB|NEWz
DLD-1 NHnVWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOwMVExODBibl2= M4XDT|Q5KGh? MlfFbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M3;UelI1PDB|NEWz
CCD18Co MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnSxNE0yODByIH7N M1TEUlQ5KGh? MlrsbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MmK0NlQ1ODN2NUO=
HepG2 Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn3PWIzPCCq MnXETWM2OD13Mj615qCK|ryP NVy1dXl{OjR|NEG2PFg>
HEK293/pcDNA3.1 NGC3dYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;ERpZHUUN3ME2wMlAxPMLzMD6wNFA{KM7:TR?= M3nMTVI1Ojh2N{iz
HEK293/MRP1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[0dmlEPTB;MD6wOVXDuTBwMEGyNEDPxE1? MVmyOFI5PDd6Mx?=
Ramos MUPBdI9xfG:|aYOgRZN{[Xl? M2\rbVLjiIoQvF2= MUO0PEBp MYrpcoR2[2W|IEO0MlYmyrFzLkmyKUBieG:ydH;zbZM> NYfyR2JGOjR{NU[0PVE>
NCI-H1299/pcDNA3 MnSzR4VtdCCYaXHibYxqfHliQYPzZZk> MkfPNE0zOCCwTR?= MmW3PVYhcA>? NETheoVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NF7jepkzPDF5N{CxNi=>
H1299/ICAM-3 MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NEP5XXMxNTJyIH7N M{HZflk3KGh? NX;HSFh5cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NHnLfZQzPDF5N{CxNi=>
NCI-H1299/pcDNA3 NGfmTHVHfW6ldHnvckBCe3OjeR?= NI\ldWkyNzVxMUCvNlDDqG6P MlXmPVYhcA>? M37EOIlv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA> MnLsNlQyPzdyMUK=
H1299/ICAM-3 MV\GeY5kfGmxbjDBd5NigQ>? NITIZXMyNzVxMUCvNlDDqG6P NF7vdFM6PiCq MkHWbY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=> M3L6eFI1OTd5MEGy
W1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMECzNkDPxE1? NEXTPIIzPDF2MEG3Oi=>
W1VR MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG2TWM2OD1yLkC1OkDPxE1? MVKyOFE1ODF5Nh?=
K562 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLVemRKSzVyPUCuNFMzKMLzIECuNFAyKCEQvF2= MV:yOFE{PTl|Nx?=
K562/ADR NF3qd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXRXZNDUUN3ME2zMlI3OSEEsTCwMlQyOiEQvF2= NV;McXIxOjRzM{W5N|c>
K562 MnrYRZBweHSxc3nzJGF{e2G7 M4ToblAvOyEQvF2= MmTuNlQhcA>? NVvaVJhCcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= MWCyOFE{PTl|Nx?=
K562/ADR MWfBdI9xfG:|aYOgRZN{[Xl? M4HGSlMh|ryP MVKyOEBp M3rPNYlv\HWlZYOgZZBweHSxc3nz NWr6RopqOjRzM{W5N|c>
A549 NXLM[Jp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPCdXNKSzVyPUCuNVAhyrFiMD6wN{DPxE1? MVWyN|k4OTB5NR?=
K562 NW\xTZprS2WubDDWbYFjcWyrdImgRZN{[Xl? NXXCTo15Oy55NfMAl|YxyqCwTR?= MVG3NuKhcMLi NEHaSphqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MVqyN|g4PzJ{Mx?=
lucena NGrYZVFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHrsZ4g{Njd34pETOlDDqG6P NUL1c5NMPzMEoHlCpC=> NGfDfpRvdyCnZn\lZ5Q> NWHMW3dmOjN6N{eyNlM>
FEPS NGTKcphE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFrBemI{Njd34pETOlDDqG6P M1vxT|czyqCqwrC= NFn0b25vdyCnZn\lZ5Q> MX:yN|g4PzJ{Mx?=
A2780 NV33WGxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPwTplKSzVyPUOuOUBuVQ>? NIH1TpQzOzh{OUKwNy=>
ACHN NULHcY9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH3fXJKSzVyPECuNUBuVQ>? NITZTJAzOzh{OUKwNy=>
U-937 NED3dpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfDTWM2ODx|NDDuUS=> NUPSS|U2OjN6MkmyNFM>
Jurkat NHvPRVBCeG:ydH;zbZMhSXO|YYm= M4HDe|XDqM7:Zz;tcOKh Mn3YNlQhcA>? NUDucFBkcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= M4rmSFI{QDFyNEC5
Jurkat Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW1xsDPxGdxbX|CpC=> MkHFNlQhcA>? NXTiPJBk[XK{ZYP0JGp2emujdDDj[YxteyCrbjDHNk9OKHCqYYPl MVSyN|gyODRyOR?=
Hep-2 M2X1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PDNmlEPTB;MD6wOOKyOC5yMTFOwG0> M{L1dVI{PzhyNEK0
Hep-2/v M1rFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUKzVGFXUUN3ME2xMljDuTBwMkCg{txO NVPBUG4xOjN5OEC0NlQ>
SGC-7901 NFfKOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfMOJdiOC1zMDFOwIcwdWx? NEflSZYzPC92OD:3NkBp M{fVd4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NEfGO4MzOzd2M{W3Ni=>
SGC-7901/VCR NV:3UpRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLENE0yOCEQvHevcYw> MlfMNlQwPDhxN{KgbC=> MoPqbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NYO3OGNiOjN5NEO1O|I>
SGC-7901 MkjGRZBweHSxc3nzJGF{e2G7 NF7BSIdqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NFrTfIYzOzd2M{W3Ni=>
SGC-7901/VCR MYfBdI9xfG:|aYOgRZN{[Xl? Ml[5bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MX6yN|c1OzV5Mh?=
KB-3-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFwNk[gxtEhOC5zNkKg{txO MlH6NlM3PzN2NEW=
KB-C2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHkXIdKSzVyPUKwNk42PiEEsTC0Nk41QDFizszN MkHoNlM3PzN2NEW=
KB-3-1 NHTo[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37oN2lEPTB;MT6yOkDDuSByLkCyO{DPxE1? M4S3elI{Pjd|NES1
KB-V1 M{jURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDCTWM2OD1{MEiuPFUhyrFiMkCuOEDPxE1? M4fXT|I{Pjd|NES1
HEK293/pcDNA3.1 M3Hibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOwbYtKSzVyPUK0MlEhyrFiMD6yNFQh|ryP NFPKSJMzOzZ5M{S0OS=>
HEK293/ABCB1 M4q5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTJTWM2OD1|NUGyMlghyrFiM{e4MlM6OSEQvF2= M17pZ|I{Pjd|NES1
A549/EGFP  M4XtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX0NE4xOS1zMECwJO69VQ>? M1Pwc2lEPTB;OE[uO{DDuSB{OT6xJO69VQ>? MkPQNlM3OzR{OEK=
A549/Slug MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PFS|AvODFvMUCwNEDPxE1? MnjWTWM2OD17LkegxtEhOy5zIN88US=> NX\tU5R3OjN4M{SyPFI>
JFCR39  NI\Ocm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWexJOK2VQ>? MXuyOEBp MoDZSG1UVw>? NGnW[I5u[XKtZXTsfUBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDHNk9OKHCqYYPlJINmdGy| MnzLNlM2QTh{N{[=
A549 MY\GeY5kfGmxbjDBd5NigQ>? NIfDXVEyODBibl2= M3u1TlE3KGh? MlXwSG1UVw>? Ml:ycIVi\HNidH:gZUBtd3O|IH;mJI1q[3KxdIXieYxmew>? NU\EZ2I{OjN3OUiyO|Y>
SGC7901 Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;L[mlEPTB;MT6yOwKBkcLz4pEJNE4yOSEQvHevcYw> NFjFO40zOzV4NES4Ni=>
SGC7901/LV-NC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnsXJJKSzVyPUGuO|fjiIoEsfMAjVAvOTZizsznM41t NEXVRpozOzV4NES4Ni=>
SGC7901/LV-SGO1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7Kd2FKSzVyPUSuN|bjiIoEsfMAjVAvOzdizsznM41t NIPrdIYzOzV4NES4Ni=>
SGC7901/VCR NILJPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXntT|lkUUN3M{2yNE42O+LCidMx5qCKOS57NjFOwIcwdWx? MV:yN|U3PDR6Mh?=
SGC7901/VCR-NC M2qzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfkPWNKSzVyPUG5Mlg36oDLwsJihKkzNjBzIN88[{9udA>? NYTSTWVYOjN3NkS0PFI>
SGC7901/VCR-si-SGO1 MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq1TWM2OD14LkG45qCKyrIkgJmxMlA{KM7:Zz;tcC=> NFu3coczOzV4NES4Ni=>
SGC7901/ADR MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDtTWM2OD15Lki15qCKyrIkgJmwMlY1KM7:Zz;tcC=> M3juOVI{PTZ2NEiy
SGC7901/ADR-NC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrDTWM2OD16Lkmz5qCKyrIkgJmwMlY5KM7:Zz;tcC=> NIiycZgzOzV4NES4Ni=>
SGC7901/ADR-si-SGO1 M{\DR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfjTWM2OD1|LkS25qCKyrIkgJmwMlI6KM7:Zz;tcC=> MYqyN|U3PDR6Mh?=
SH-SY5Y  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWqwMlAxOS1zMDFOwG0> M1flOFI1KGh? MWrJR|UxRTBwMUGzxtExNjBzMjFOwG0> Mo\iNlMyOjlyNkW=
SH-SY5Y  M33DR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjGVVhGOC5yMEGtNVAh|ryP Mm\POFghcA>? NFLaXI5KSzVyPUCuNFc5yrFyLkCwPUDPxE1? NFjGeFAzOzF{OUC2OS=>
SH-SY5Y  M1K3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPONE4xODFvMUCg{txO NGLmRZM4OiCq M4rUNGlEPTB;MD6wOVHDuTBwMEC4JO69VQ>? MoLyNlMyOjlyNkW=
SH-SY5Y NG\KOWlCeG:ydH;zbZMhSXO|YYm= NFnv[mMxNjFizszN Mny0NE0zPCCq MYLpcoR2[2W|IHHwc5B1d3OrczDv[kBUUC2VWUXZJINmdGy|IH\vcIxwf2mwZzDj[YxtKGO7Y3zlJIFzemW|dDDheEB1cGViR{KvUUBxcGG|ZR?= Ml65NlMyOjlyNkW=
SH-SY5Y M1vvS2Fxd3C2b4Ppd{BCe3OjeR?= NHSwUGIxNjFizszN M{P3O|AuOjRiaB?= MnS1bY5lfWOnczDtbZRwfGmlIHHydoV{fMLi NIHUcXEzOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol slightly soluble or insoluble
In vivo Saline 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03023358 Not yet recruiting Peripheral T Cell Lymphoma Nanfang Hospital of Southern Medical University February 2017 Phase 3
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03003520 Recruiting Lymphoma, Large B-Cell, Diffuse Celgene February 2017 Phase 2
NCT03018626 Not yet recruiting Lymphoma, Large B-Cell, Diffuse Nanfang Hospital of Southern Medical University February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID